Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Introducing the 2019 ESC Guidelines on Diabetes, Pre-Diabetes, and CVD

Abstract : Secondary prevention in patients with coronary artery disease and peripheral artery disease involves antithrombotic therapy and optimal control of cardiovascular risk factors. In the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) study, adding low-dose rivaroxaban on top of aspirin lowered cardiovascular events, but there is limited data about risk factor control in secondary prevention. We studied the association between risk factor status and outcomes, and the impact of risk factor status on the treatment effect of rivaroxaban, in a large contemporary population of patients with coronary artery disease or peripheral artery disease.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-unilim.archives-ouvertes.fr/hal-02448999
Contributeur : Elisabeth Grelier <>
Soumis le : mercredi 22 janvier 2020 - 15:56:44
Dernière modification le : jeudi 23 janvier 2020 - 01:32:10

Lien texte intégral

Identifiants

Collections

Citation

Victor Aboyans. Introducing the 2019 ESC Guidelines on Diabetes, Pre-Diabetes, and CVD. European Heart Journal, Oxford University Press (OUP): Policy B, 2019, 40 (39), pp.3217-3219. ⟨10.1093/eurheartj/ehz688⟩. ⟨hal-02448999⟩

Partager

Métriques

Consultations de la notice

52